Consistently, combined neutralization of such proangiogenic factors has better efficacy than VEGF monotherapy in animal disease models,[40] and a bispecific antibody drug, faricimab, has recently been approved for the treatment of ocular diseases.[21b] These considerations support the proposition that a TRAP1 inhibition strategy could be effective for the treatment of ischemic retinopathies, which would inactivate the upstream master regulator HIF1α to simultaneously block pathological up‐regulation of multiple angiogenic regulators. The gene discussed is HIF1A; the disease is non-human animal disease.